The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies.

about

Cell death-based approaches in treatment of the urinary tract-associated diseases: a fight for survival in the killing fields.Prostatic cancers: understanding their molecular pathology and the 2016 WHO classification.

P2860

Q47711163-82F69847-4F62-41A5-A44F-D2462739FAEF Q52629153-BCD7CCCF-D639-4B62-A08E-F80E2282CEF8

P2860

The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies.

Item

http://www.wikidata.org/entity/Q39190147

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

The emerging role of homologou ...... in genitourinary malignancies.

@en

The emerging role of homologou ...... in genitourinary malignancies.

@nl

type

Item

label

The emerging role of homologou ...... in genitourinary malignancies.

@en

The emerging role of homologou ...... in genitourinary malignancies.

@nl

prefLabel

The emerging role of homologou ...... in genitourinary malignancies.

@en

The emerging role of homologou ...... in genitourinary malignancies.

@nl

P1476

The emerging role of homologou ...... in genitourinary malignancies

@en

P2093

Joshua J Meeks

http://www.w3.org/2001/XMLSchema#string

Kalen J Rimar

http://www.w3.org/2001/XMLSchema#string

Maha Hussain

http://www.w3.org/2001/XMLSchema#string

Richard S Matulewicz

http://www.w3.org/2001/XMLSchema#string

P2860

Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer

Homologous-recombination-deficient tumours are dependent on Polθ-mediated repair

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.

Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity.

Integrative clinical genomics of advanced prostate cancer.

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

P304

1912-1924

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.30631

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

123

http://www.w3.org/2001/XMLSchema#string

P50

Phuoc T. Tran

P577

2017-03-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28323334

http://www.w3.org/2001/XMLSchema#string

P932

5457906

http://www.w3.org/2001/XMLSchema#string

The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies.

about

P2860

P2860

The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932